Clinical Profile of Late-Infantile and Juvenile Metachromatic Leukodystrophy: A Retrospective Study

Year 2022, Volume: 75 Issue: 4, 544 - 549, 20.01.2023

Ceren Günbey , Didem Ardıçlı , Kader Karlı Oğuz Meral Topçu

Abstract

Objectives: Metachromatic leukodystrophy (MLD) is a glycosphingolipid storage disease leading to demyelination and neurological impairment.
Based on the age at onset, late-infantile, juvenile, and adult forms are defined. In this study, our aim was to define the clinical characteristics in
late-infantile and juvenile forms.

Materials and Methods: Twelve children with either late-infantile or juvenile form of MLD were enrolled. Patient records were retrospectively
analyzed to gather demographic, clinical, laboratory, and imaging data.
Results: Patients had a median age of 2 years (1.5-15) at the onset of symptom. Five (41.7%) patients had family history of MLD. Seven (58.3%)
children were diagnosed as late-infantile form while 5 (41.7%) children were classified as juvenile form. In the late-infantile group, gait impairment
(7/7, 100%) was the primary symptom, whereas behavioral/cognitive impairment (4/5, 80%) predominated the juvenile group. Eleven patients
(91.7%) had cognitive impairment at the time of admission. Only one patient (8.3%) had epilepsy. While none of the patients in the juvenile group
lost ambulation in follow-up, all late-infantile patients were non-ambulatory at their most recent visits.

Conclusion: Our findings, along with those of other studies, support the diverse clinical picture of these two types of MLD. It is essential to recognize
the age-specific signs to make an early diagnosis of MLD. Our findings suggest that MLD should be thoroughly investigated in children with a
neurodegenerative course. Moreover, siblings of MLD patients should also be carefully evaluated.

Keywords

Metachromatic Leukodystrophy , Late-Infantile , Juvenile , Children

Ethical Statement

Ethical approval was obtained from the Ethics Committee of Hacettepe University Faculty of Medicine (approval number: 17/511-21).

Supporting Institution

-

Project Number

-

Thanks

-

Geç İnfantil ve Jüvenil Metakromatik Lökodistrofinin Klinik Özellikleri: Retrospektif Bir Çalışma

Abstract

Amaç: Metakromatik lökodistrofi (MLD), demiyelinizasyona ve nörolojik etkilenmeye yol açan bir glikosfingolipid depo hastalığıdır. Semptomların
başlangıç yaşına göre geç infantil, jüvenil ve yetişkin formlara ayrılır. Bu çalışmada geç infantil ve juvenil formların klinik özelliklerini değerlendirmek
amaçlanmıştır.

Gereç ve Yöntem: Geç infantil veya juvenil MLD tanısını almış on iki çocuk bu çalışmaya dahil edildi. Demografik, klinik, laboratuvar ve görüntüleme
verileri geriye dönük olarak incelendi.
Bulgular: Hastaların semptom başlangıcında ortanca yaşı 2 (1,5-15) yıldı. Beş (%41,7) hastanın ailesinde MLD öyküsü vardı. Yedi (%58,3) çocuk geç
infantil form, 5 (%41,7) çocuk ise juvenil form olarak sınıflandırıldı. Geç infantil grupta yürüme bozukluğu (7/7, %100) ana semptom iken, jüvenil
grupta davranışsal/bilişsel bozukluk (4/5, %80) en yaygın semptomdu. Başvuru sırasında 11 hastada (%91,7) bilişsel etkilenme vardı. Bir hasta (%8,3)
epilepsi tanısı aldı. Jüvenil gruptaki hastalar kontrollerde hala ambulatuvar iken, geç infantil gruptaki çocukların hiçbiri son kontrolde yürüyemiyordu.

Sonuç: Literatürdeki diğer çalışmalara benzer şekilde çalışmamızın sonuçları geç infantil veya juvenil MLD formlarının birbirlerinden farklı bir klinik
seyir izlediğini göstermiştir. Erken teşhis için yaşa özgü belirtileri tanımak önemlidir. Bulgularımız, nörodejeneratif seyirli hastalık gösteren çocuklarda
MLD’nin kapsamlı bir şekilde araştırılması gerektiğini vurgulamaktadır. Ayrıca, MLD hastalarının kardeşleri de dikkatle değerlendirilmelidir.

Keywords

Metakromatik Lökodistrofi , Geç İnfantil , Jüvenil , Çocuk

Ethical Statement

-

Supporting Institution

-

Project Number

-

Thanks

-

References

• 1. Vanderver A, Prust M, Tonduti D, et al. Case definition and classification of leukodystrophies and leukoencephalopathies. Mol Genet Metab. 2015;114:494-500.
• 2. Shaimardanova AA, Chulpanova DS, Solovyeva VV, et al. Metachromatic Leukodystrophy: Diagnosis, Modeling, and Treatment Approaches. Front Med (Lausanne). 2020;7:576221.
• 3. Cesani M, Lorioli L, Grossi S, et al. Mutation Update of ARSA and PSAP Genes Causing Metachromatic Leukodystrophy. Hum Mutat. 2016;37:16-27.
• 4. Gieselmann V. Metachromatic leukodystrophy: genetics, pathogenesis and therapeutic options. Acta Paediatr. 2008;97:15-21.
• 5. Kehrer C, Blumenstock G, Gieselmann V, et al. GERMAN LEUKONET. The natural course of gross motor deterioration in metachromatic leukodystrophy. Dev Med Child Neurol. 2011;53:850-855.
• 6. Kehrer C, Groeschel S, Kustermann-Kuhn B, et al. Language and cognition in children with metachromatic leukodystrophy: onset and natural course in a nationwide cohort. Orphanet J Rare Dis. 2014;9:18.
• 7. van Rappard DF, de Vries ALC, Oostrom KJ, et al. Slowly Progressive Psychiatric Symptoms: Think Metachromatic Leukodystrophy. J Am Acad Child Adolesc Psychiatry. 2018;57:74-76.
• 8. Marcão AM, Wiest R, Schindler K, et al. Adult onset metachromatic leukodystrophy without electroclinical peripheral nervous system involvement: a new mutation in the ARSA gene. Arch Neurol. 2005;62:309-313.
• 9. Pekgül F, Eroğlu-Ertuğrul NG, Bekircan-Kurt CE, et al. Comprehensive clinical, biochemical, radiological and genetic analysis of 28 Turkish cases with suspected metachromatic leukodystrophy and their relatives. Mol Genet Metab Rep. 2020;25:100688.
• 10. Eroglu-Ertugrul NG, Yousefi M, Pekgül F, et al. Myelin oligodendrocyte glycoprotein antibodies in genetic leukodystrophies. J Neuroimmunol. 2022;369:577916.
• 11. Gieselmann V, Krägeloh-Mann I. Metachromatic leukodystrophy--an update. Neuropediatrics. 2010;41:1-6.
• 12. Fumagalli F, Zambon AA, Rancoita PMV, et al. Metachromatic leukodystrophy: A single-center longitudinal study of 45 patients. J Inherit Metab Dis. 2021;44:1151-1164.
• 13. Harrington M, Whalley D, Twiss J, et al. Insights into the natural history of metachromatic leukodystrophy from interviews with caregivers. Orphanet J Rare Dis. 2019;14:89.
• 14. Keller SR, Mallack EJ, Rubin JP, et al. Practical Approaches and Knowledge Gaps in the Care for Children With Leukodystrophies. J Child Neurol. 2021;36:65-78.
• 15. Adang LA, Sherbini O, Ball L, et al. Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies. Mol Genet Metab. 2017;122:18-32.
• 16. Bindu PS, Mahadevan A, Taly AB, et al. Peripheral neuropathy in metachromatic leucodystrophy. A study of 40 cases from south India. J Neurol Neurosurg Psychiatry. 2005;76:1698-1701.
• 17. Mahmood A, Berry J, Wenger DA, et al. Metachromatic leukodystrophy: a case of triplets with the late infantile variant and a systematic review of the literature. J Child Neurol. 2010;25:572-580.
• 18. Beerepoot S, Nierkens S, Boelens JJ, et al. Peripheral neuropathy in metachromatic leukodystrophy: current status and future perspective. Orphanet J Rare Dis. 2019;14:240.
• 19. Groeschel S, Kühl JS, Bley AE, et al. Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Juvenile Metachromatic Leukodystrophy Compared With Nontransplanted Control Patients. JAMA Neurol. 2016;73:1133-1140.
• 20. Boucher AA, Miller W, Shanley R, et al. Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report. Orphanet J Rare Dis. 2015;10:94.
• 21. Fumagalli F, Calbi V, Natali Sora MG, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access. Lancet. 2022;399:372-383.
• 22. Rosenberg JB, Chen A, De BP, et al. Safety of Direct Intraparenchymal AAVrh.10-Mediated Central Nervous System Gene Therapy for Metachromatic Leukodystrophy. Hum Gene Ther. 2021;32:563-580.
• 23. Í Dali C, Sevin C, Krägeloh-Mann I, et al. Safety of intrathecal delivery of recombinant human arylsulfatase A in children with metachromatic leukodystrophy: Results from a phase 1/2 clinical trial. Mol Genet Metab. 2020;131:235-244.